14th meeting of the ACNFP and COT Joint Subgroup on CBD and Hemp Derived Products Agenda 22nd of January 2025

CBD14/2025

Joint Subgroup of the Advisory Committee on Novel Foods and Processes (ACNFP) and Committee on Toxicity (COT) on CBD and Hemp Derived Products

The 14^{th} meeting of the ACNFP/COT CBD Subcommittee will be held at 10:00am on the 22^{nd} of January 2025 on Microsoft Teams.

Members are reminded of the need to announce any commercial interests in the business of the Committee prior to the discussions on each item.

In accordance with agreed procedures, the Secretariat is duty bound to keep a record of the names of Members who have declared interests at meetings of the Committee, giving dates, names of relevant products and companies, details of the interest declared, and whether the Member took part in the proceedings.

ACNFP/COT Secretariat

January 2025

14th Meeting of the ACNFP/COT Subcommittee on CBD and Hemp Derived Products - 22nd January 2025 Agenda

- 1. Apologies and Announcements.
- 2. Welcome and Introductions.

- 3. Minutes from the previous meeting The Subgroup will review the minutes from the meeting in November 2024.
- 4. Matters arising The Subgroup will be updated on the matters arising from the previous meeting
- 5. Investigating The Source Of Variation In The Toxicological Profile Of Group C CBD Novel Foods (Hemp Extracts) Compared To The CBD Content the Subgroup will further review the toxicological data for hemp extract novel foods and finalise the advice to be provided to the ACNFP. CBD14/2025/01
- 6. Review Of Draft Summary Of FSA Evidence Base For CBD From The CBD Novel Food Applications The Subgroup will review and finalise the database summarising their advice to the ACNFP on the CBD sub chronic toxicological data. CBD14/2025/02
- 7. Review Of Further Information From The Published Literature On The Toxicological Profile Of 98% Or Greater Purity CBD The Subgroup will review Lachenmeier et al., 2023 and explore the role of publish data in the review of CBD novel food applications of 98% or above purity. CBD14/2025/03
- 8. AOB Close